Understanding hypertriglyceridemia in women: Clinical impact and management with prescription omega-3-acid ethyl esters

International Journal of Women's Health

Volumn 3, Issue 1, 2011, Pages 87-97

  Dayspring, Thomas D ^a  

^a North Jersey Institute of Menopausal Lipidology   (United States)

Author keywords

Lipids; Lovaza; Omega 3; P OM3; Triglycerides; Women

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID ESTER; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR RISK; DIETARY INTAKE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIPID METABOLISM; MENOPAUSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79952820994     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S16702     Document Type: Article

References (71)

1. Ford ES, Li C, Zhao G, et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Int Med. 2009;169(6):572-578.
2. Blaha M, Blumenthal R, Brinton E, Jacobson T. The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol. 2008;2(4):267-273.
3. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992;70(19):3H-9H.
4. Knopp RH, Paramsothy P, Atkinson B, Dowdy A. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Am J Cardiol. 2008;101(8A): 48B-57B.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA. 2001;285(19):2486-2497.
6. Henderson JT, Weisman CS. Women's patterns of provider use across the lifespan and satisfaction with primary care coordination and comprehensiveness. Med Care. 2005;43(8):826-833.
7. Packard CJ, Demant T, Stewart JP, et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res. 2000; 41:305-317.
8. Bays H. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians. Drugs Today (Barc). 2008;44(3):205-246.
9. Lichtenstein AH. Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res. 2006;47(8):1661-1667.
10. Rader D, Hobbs H. Chapter 350. Disorders of lipoprotein metabolism. In: Fauci A, Braunwald E, Kasper D, et al, eds. Harrison's Principles of Internal Medicine. http://www.accessmedicine.com/content.aspx?aID=2882429. Accessed January 12, 2011.
11. Brewer HB Jr. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol. 1999;83(9B):3F-12F.
12. Langer T, Strober W, Levy RI. The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J Clin Invest. 1972;51(6): 1528-1536.
13. Caslake MJ, Packard CJ. Phenotypes, genotypes and response to statin therapy. Curr Opin Lipidol. 2004;15(4):387-392.
14. El Harchaoui K, van der Steeg W, Stroes E, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49(5):547-553.
15. Dayspring T. High-density lipoproteins: emerging knowledge. Cardiometab Syndr. 2007;2(1):59-62.
16. Georgieva AM, van Greevenbroek MM, Krauss RM, et al. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler Thromb Vasc Biol. 2004;24(4):744-749.
17. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83(9B):25F-29F.
18. Guerin M, Le Goff W, Lassel TS, et al. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol. 2001;21(2):282-288.
19. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81(4A):18B-25B.
20. Toth PP, Dayspring TD, Pokrywka GS. Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids. Curr Atheroscler Rep. 2009;11(1):71-79.
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-3421.
22. Lloyd-Jones DM, O'Donnell CJ, D'Agostino RB, et al. Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham Heart Study. Arch Int Med. 2001;161(7):949-954.
23. Mosca LJ. Optimal management of cholesterol levels and the prevention of coronary heart disease in women. Am Fam Phys. 2002;65(2): 217-226.
24. American Diabetes Association. Winning at work: diabetes facts. http://www.diabetes.org/communityprograms-and-localevents/waw-diabetesfacts.jsp. Accessed January 2, 2011.
25. Kolovou GD, Bilianou HG. Influence of aging and menopause on lipids and lipoproteins in women. Angiology. 2008;59(Suppl 2):54S-57S.
26. Solhpour A, Parkhideh S, Sarrafzadegan N, et al. Levels of lipids and apolipoproteins in three cultures. Atherosclerosis. 2009;207(1):200-207.
27. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005;294(14):1773-1781.
28. Derby CA, Crawford SL, Pasternak RC, et al. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol. 2009;169(11): 1352-1361.
29. Carr M. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88(6):2404-2411.
30. Sowers M, Zheng H, Tomey K, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab. 2007;92(3):895-901.
31. Piche ME, Lapointe A, Weisnagel SJ, et al. Regional body fat distribution and metabolic profile in postmenopausal women. Metab Clin Exp. 2008;57(8):1101-1107.
32. Tchernof A, Desmeules A, Richard C, et al. Ovarian hormone status and abdominal visceral adipose tissue metabolism. J Clin Endocrinol Metab. 2004;89(7):3425-3430.
33. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007; 115(4): 450-458.
34. Tanko LB, Bagger YZ, Qin G, et al. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005;111(15):1883-1890.
35. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299-308.
36. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359.
37. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(Suppl M):M8-M14.
38. Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol. 2009; 20(6):497-504.
39. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-822.
40. Liu J, Sempos CT, Donahue RP, et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98(10):1363-1368.
41. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
42. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115(11):1481-1501.
43. Dayspring T, Helmbold A. You have a new job: monitor the lipid profile. OBG Management. 2008;20(12):227-239.
44. Mosca L, Mochari H, Christian A, et al. National study of women's awareness, preventive action, and barriers to cardiovascular health. Circulation. 2006;113(4):525-534.
45. Cooke CE, Hammerash WJ Jr. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization. Clin Ther. 2006;28(4):591-599.
46. Stein EA, Sniderman A, Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol. 2005;96(9A):36K-43K; discussion 34K-35K.
47. Weingartner O, Lutjohann D, Ji S, et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol. 2008;51(16): 1553-1561.
48. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114(1): 82-96.
49. Bantle JP, Wylie-Rosett J, Albright AL, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31(Suppl 1): S61-S78.
50. US Department of Health and Human Services and US Department of Agriculture. Dietary guidelines for Americans, 2005. 6th ed. Washington, DC: US Government Printing Office; 2005.
51. Kris-Etherton PM, Innis S. American Dietetic Association, Dietitians of Canada. Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids. J Am Diet Assoc. 2007;107(9): 1599-1611.
52. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002; 106(21):2747-2757.
53. Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr. 2008;87(6): 1981S-1990S.
54. Oh RC, Beresford SA, Lafferty WE. The fish in secondary prevention of heart disease (FISH) survey: primary care physicians and omega3 fatty acid prescribing behaviors. J Am Board Fam Med. 2006;19(5): 459-467.
55. Harris WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65(Suppl 5):1645S-1654S.
56. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96(4):556-563.
57. Davidson MH, Ballantyne CM, Kerzner B, et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004;58(8):746-755.
58. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(7):1354-1367.
59. LOVAZA [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
60. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997; 4(5-6):385-391.
61. Pownall HJ, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143(2):285-297.
62. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3): 391-409.
63. Goldberg AC, Schonfeld G, Feldman EB, et al. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebocontrolled multicenter US study. Clin Ther. 1989;11(1):69-83.
64. Calabresi L, Donati D, Pazzucconi F, et al. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis. 2000;148(2):387-396.
65. Bays H, Maki K, McKenney J, et al. Long-term up to 24 month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin. 2010; 26(4):907-915.
66. Davidson M, Maki K, Bays H, et al. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2009;3(5): 332-340.
67. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Resear. 2005; 36(3):232-240.
68. Maki KC, McKenney JM, Reeves MS, et al. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol. 2008;102(4):429-433.
69. Maki K, Lubin B, Reeves M, Dicklin M, et al. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia. J Clin Lipidol. 2009;3(1):33-38.
70. Bays H, McKenney J, Maki KC, et al. Prescription omega-3-acid ethyl esters: effects on non-high-density lipoprotein cholesterol in combined hyperlipidemic patients when co-administered with escalating doses of atorvastatin. Mayo Clin Proc. 2010;85:122-128.
71. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clinical Chemistry. 2009;55:3:407-419.